Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.2.0.727
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2013
Cash flows from operating activities:      
Net earnings $ 107,735,000 $ 110,948,000 $ 112,561,000
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 37,226,000 19,175,000 12,321,000
Costs recognized on sale of acquired inventory 6,961,000 7,480,000 4,501,000
Deferred income taxes 1,304,000 (2,853,000) (2,534,000)
Stock-based compensation expense 5,957,000 3,523,000 1,864,000
Gain on sale of CyVek (8,300,000) 0 0
Excess tax benefit from stock option exercises (615,000) (262,000) (75,000)
Net (gain) loss from equity method investees 0 0 (570,000)
Other 458,000 592,000 763,000
Change in operating assets and liabilities, net of acquisitions:      
Trade accounts and other receivables (11,747,000) 1,145,000 (2,334,000)
Inventories (4,714,000) (2,895,000) (2,216,000)
Prepaid expenses (620,000) (554,000) (33,000)
Trade accounts payable and accrued expenses 2,154,000 1,368,000 243,000
Salaries, wages and related accruals 1,679,000 1,034,000 (92,000)
Income taxes payable 1,881,000 (1,939,000) (837,000)
Net cash provided by operating activities 139,359,000 136,762,000 123,562,000
Cash flows from investing activities:      
Purchase of available-for-sale investments 0 (106,746,000) (112,712,000)
Proceeds from sale and maturities of available-for-sale investments 13,466,000 289,410,000 103,610,000
Additions to property and equipment (19,905,000) (13,821,000) (22,454,000)
Acquisitions, net of cash acquired (420,102,000) (109,180,000) 0
Investment in unconsolidated entity 0 (10,000,000) 0
Other 48,000 25,000 352,000
Net cash provided by (used in) investing activities (426,493,000) 49,688,000 (31,204,000)
Cash flows from financing activities:      
Cash dividends (47,106,000) (45,394,000) (43,463,000)
Proceeds from stock option exercises 9,731,000 8,326,000 1,105,000
Excess tax benefit from stock option exercises 615,000 262,000 75,000
Purchase of common stock for stock bonus plans 0 0 (573,000)
Repurchase of common stock 0 0 (1,821,000)
Borrowings under line-of-credit agreement 163,000,000 0 0
Payment on line-of-credit and other (94,964,000) 0 0
Net cash used in financing activities 31,276,000 (36,806,000) (44,677,000)
Effect of exchange rate changes on cash and cash equivalents (8,178,000) 5,138,000 (570,000)
Net change in cash and cash equivalents (264,036,000) 154,782,000 47,111,000
Cash and cash equivalents at beginning of year 318,568,000 163,786,000 116,675,000
Cash and cash equivalents at end of year $ 54,532,000 $ 318,568,000 $ 163,786,000